2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What External and Internal Drivers Are Contributing to the Growth of theGlioblastoma Multiforme Market?
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain’s structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population, longer life expectancy, lifestyle changes, and better diagnostic technologies. Understanding these disorders advances research on glioblastoma multiforme (GBM), which leads to improved early detection, novel treatments, and better patient outcomes. By examining neurological diseases, researchers can identify genetic and molecular factors contributing to GBM development. For example, in February 2025, Dementia Australia, a non-profit organization, reported that around 433,300 Australians were living with dementia, with that number projected to increase to 812,500 by 2054. Moreover, younger-onset dementia will affect approximately 29,000 people in 2025, with projections rising to 41,000 by 2054. As a result, the rising prevalence of brain disorders will drive the growth of the glioblastoma multiforme market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp
#What is the Anticipated CAGR of theGlioblastoma Multiforme Market, and What Factors Will Drive It?
The glioblastoma multiforme market has grown strongly, increasing from $2.50 billion in 2024 to $2.71 billion in 2025 at a CAGR of 8.3%. Key growth factors include a rising incidence of glioblastoma multiforme, improvements in healthcare infrastructure, increased awareness, greater access to advanced therapies, and an aging population.
The glioblastoma multiforme market is expected to grow steadily, reaching $3.69 billion by 2029 at a CAGR of 8.1%. Contributing factors include a rising number of brain and nervous system cancer cases, growing acceptance of surgical techniques, increased disease awareness, early diagnosis initiatives, and a surge in R&D activities. Emerging trends include advancements in medical technology, improvements in imaging techniques, the expansion of personalized medicine, AI-driven diagnostics, and continued progress in scientific and technological research.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21191
Which Upcoming Market Trends and Innovations Are Set to Influence theGlioblastoma Multiforme Market’s Path Forward?
In the glioblastoma multiforme (GBM) market, companies are advancing therapies like CAR T-cell treatments to meet the needs of patients with aggressive cancers. CAR T-cell therapies modify a patient’s own T-cells to target cancer cells more effectively. In June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, launched a Phase IB clinical trial of CHM 1101 (CLXT CAR T) therapy for recurrent or progressive glioblastoma multiforme. The trial is evaluating the safety and efficacy of the treatment, and initial Phase 1a results have shown disease stability, with plans to proceed to a Phase 2 trial based on the findings.
Who Are the Dominant Market Players Pushing the Boundaries of theGlioblastoma Multiforme Market?
Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report
What Are the Core Segments of the Glioblastoma Multiforme Market, and How Do They Contribute to Growth?
The glioblastoma multiforme market covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21191&type=smp
What Regions Are Dominating the Glioblastoma Multiforme Market Growth?
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Glioblastoma Multiforme Market 2025, By The Business Research Company:
Bleeding Disorders Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report
Bleeding Disorder Testing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bleeding-disorder-testing-global-market-report
Small Cell Lung Cancer Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
